Physical Improvement and Biological Maturity of Young Athletes (11-12 Years) with Systematic Training.

AIM: The aim of this study was to investigate the influence of systematic training in physical growth and biological maturity in prepubertal males and estimate how this affects the physical growth and skeletal maturity. MATERIALS AND METHODS: 177 primary school students of the fifth and sixth grade, from schools in Alexandroupolis, participated voluntarily in our study. Questionnaires were used in order to measure physical activity levels. The subjects were subdivided into two groups; control group (prepubertal, whose physical activity was the physical education of their school and which had never participated in systematic training, n = 95) and experimental group (prepubertal, whose weekly physical activity included physical education in their schools and additionally 3-4 training units organized training in various sports clubs in the city, n = 82). The following parameters were recorded: biological age measured by determination of skeletal age; bone density measured by ultrasound methods; anthropometric and morphological features such as height, body composition, selected diameters, circumferences and skinfolds; motor ability features. RESULTS: The experimental group exhibited older biological age (p = 0.033), higher bone density (p < 0.001), lower BMI and body fat (p < 0.001), better anthropometric features and higher performance throughout all motor ability tests (p < 0.05), compared to the control group. CONCLUSION: The present study demonstrates that systematic physical activity has a positive effect on both the physical and biological maturity of pre-pubertal children. This effect is mainly expressed in bone strengthening as a result of the increased bone density and in improvement of the kinetic skills of pupils who participated in organized extracurricular sport-activities.

Bevacizumab, capecitabine, amifostine, and preoperative hypofractionated accelerated radiotherapy (HypoArc) for rectal cancer: a Phase II study.

PURPOSE: Bevacizumab has established therapeutic activity in patients with metastatic colorectal cancer, and anti-vascular endothelial growth factor therapy enhances the activity of radiotherapy in experimental models. We assessed the feasibility and efficacy of preoperative radiochemotherapy combined with bevacizumab in patients with rectal cancer. METHODS AND MATERIALS: Nineteen patients with radiologic T3 and/or N+ rectal carcinoma were treated with preoperative conformal hypofractionated accelerated radiotherapy (3.4 Gy in 10 consecutive fractions) supported with amifostine (500-1,000 mg daily), capecitabine (600 mg/m(2) twice daily, 5 days per week), and bevacizumab (5 mg/kg every 2 weeks for 2 cycles). Surgery followed 6 weeks after the end of radiotherapy. A cohort of 14 sequential patients treated with the same regimen without bevacizumab was available for comparison. RESULTS: Grade 2 or 3 diarrhea was noted in 7 of 19 patients (36.8%), which was statistically worse than patients receiving the same regimen without bevacizumab (p = 0.01). A higher incidence of Grade 2 or 3 proctalgia was also noted (21.1%) (p = 0.03). Bladder and skin toxicity was negligible. All toxicities regressed completely within 2 weeks after the end of therapy. Pathologic complete and partial response was noted in 7 of 19 cases (36.8%) and 8 of 19 cases (42.1%). Within a median follow-up of 21 months, none of the patients has had late complications develop and only 1 of 18 evaluable cases (5.5%) has had locoregional relapse. CONCLUSIONS: Bevacizumab can be safely combined with hypofractionated radiotherapy and capecitabine as a preoperative radiochemotherapy regimen for patients with rectal cancer. The high pathologic complete response rates urges the testing of bevacizumab in randomized studies.

One-lung ventilation and HIF1alpha expression in lung cancer and pneumothorax.

BACKGROUND/AIM: A prospective study was designed to investigate the effects of anesthesia, particularly that of the one-lung ventilation procedure (OLV), on the expression of hypoxia-inducible factor 1alpha (HIF1alpha) in patients with lung carcinomas and pneumothorax. MATERIALS AND METHODS: The immunohistochemical expression of HIF1alpha was studied in formalin-fixed paraffin-embedded tissues from 60 patients who had undergone thoracic surgery for lung cancer (n=48) or pneumothorax (n=12) under OLV general anesthesia. RESULTS: There was a significant, and rather unexpected, association of HIF1alpha expression with high body mass index (BMI) (p=0.01) and high body weight (p=0.01) of patients with lung carcinomas, but other anesthesia-related parameters, including analysis of arterial oxygen partial tension and anthropometric factors remained insignificant. With regard to pneumothorax cases, these were immunohistochemically unreactive and, hence, no relationship was noted between HIF1alpha and anesthesia parameters. CONCLUSION: Anesthesia and OLV procedure performed for lung cancer or pneumothorax does not affect the expression of HIF1alpha. However, the significant link between high BMI and HIF1alpha expression noted in patients with lung carcinomas brings forward a possible connection between obesity and hypoxia-related molecular pathways.